Gerald Preston

Array ( [id] => 2887215 [patent_doc_number] => 05209929 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-05-11 [patent_title] => 'Immunization against Babesiosis using purified merozoite surface antigens of Basesia bigemina' [patent_app_type] => 1 [patent_app_number] => 7/663255 [patent_app_country] => US [patent_app_date] => 1991-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7556 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/209/05209929.pdf [firstpage_image] =>[orig_patent_app_number] => 663255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2856763 [patent_doc_number] => 05112945 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1992-05-12 [patent_title] => 'Preparation of islet amyloid polypeptides (IAPP) and antibodies to IAPP' [patent_app_type] => 1 [patent_app_number] => 7/658442 [patent_app_country] => US [patent_app_date] => 1991-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5349 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/112/05112945.pdf [firstpage_image] =>[orig_patent_app_number] => 658442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2886470 [patent_doc_number] => 05268454 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-12-07 [patent_title] => 'Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier' [patent_app_type] => 1 [patent_app_number] => 7/652648 [patent_app_country] => US [patent_app_date] => 1991-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5707 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/268/05268454.pdf [firstpage_image] =>[orig_patent_app_number] => 652648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3809199 [patent_doc_number] => 05709859 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-01-20 [patent_title] => 'Mixed specificity fusion proteins' [patent_app_type] => 1 [patent_app_number] => 7/645522 [patent_app_country] => US [patent_app_date] => 1991-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5567 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/709/05709859.pdf [firstpage_image] =>[orig_patent_app_number] => 645522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 2948778 [patent_doc_number] => 05180814 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1993-01-19 [patent_title] => 'Tumor specific monoclonal antibodies' [patent_app_type] => 1 [patent_app_number] => 7/645069 [patent_app_country] => US [patent_app_date] => 1991-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 12037 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/180/05180814.pdf [firstpage_image] =>[orig_patent_app_number] => 645069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3087366 [patent_doc_number] => 05284935 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-02-08 [patent_title] => 'MHC-mediated toxic conjugates useful in ameliorating autoimmunity' [patent_app_type] => 1 [patent_app_number] => 7/635840 [patent_app_country] => US [patent_app_date] => 1990-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 21 [patent_no_of_words] => 15987 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/284/05284935.pdf [firstpage_image] =>[orig_patent_app_number] => 635840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3065563 [patent_doc_number] => 05310892 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-05-10 [patent_title] => 'Nucleic acid sequence which codes for and expresses human fibrillarin and uses thereof' [patent_app_type] => 1 [patent_app_number] => 7/626680 [patent_app_country] => US [patent_app_date] => 1990-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3914 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/310/05310892.pdf [firstpage_image] =>[orig_patent_app_number] => 626680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3021514 [patent_doc_number] => 05288854 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-02-22 [patent_title] => 'Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1' [patent_app_type] => 1 [patent_app_number] => 7/618286 [patent_app_country] => US [patent_app_date] => 1990-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 20450 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/288/05288854.pdf [firstpage_image] =>[orig_patent_app_number] => 618286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3085298 [patent_doc_number] => 05284827 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1994-02-08 [patent_title] => 'Systemic treatment of metastatic cancer with platelet factor 4' [patent_app_type] => 1 [patent_app_number] => 7/600472 [patent_app_country] => US [patent_app_date] => 1990-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6963 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/284/05284827.pdf [firstpage_image] =>[orig_patent_app_number] => 600472 [rel_patent_id] =>[rel_patent_doc_number] =>)